Literature DB >> 10799273

Rare variants in the promoter of the fragile X syndrome gene (FMR1).

M Milà1, S Castellví-Bel, A Sánchez, A Barceló, C Badenas, J Mallolas, X Estivill.   

Abstract

Fragile X syndrome, the most common form of familial mental retardation, is mainly caused by the expansion of an unstable region of CGG repeats in the 5' untranslated region of the FMR1 (Fragile X Mental Retardation-1) gene. Molecular tools to detect an abnormal CGG expansion in FMR1 include Southern blot hybridization and PCR amplification. Southern blotting with the StB12.3 probe and Eco RI/Eag I double digestion is widely used as a routine test for fragile X syndrome diagnosis in laboratories around the world. A patient with mental retardation of unknown origin showed absence of digestion for Eag I due to a -149C-->G substitution in the CpG island of the FMR1 gene, which destroys that restriction enzyme site. Screening for other changes around that region also detected a -154insGGC in a patient with a phenotype highly suggestive of fragile X syndrome but without CGG expansion. Expression studies did not show any abnormal changes in FMR1 function. In summary, we have identified two different changes (a C to G substitution at -149 and a GGC insertion at -154) in the promoter of the FMR1 gene. These are the first variants described in the promoter of the FMR1 gene. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799273     DOI: 10.1006/mcpr.2000.0293

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  6 in total

1.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

2.  Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males.

Authors:  Stephen C Collins; Steven M Bray; Joshua A Suhl; David J Cutler; Bradford Coffee; Michael E Zwick; Stephen T Warren
Journal:  Am J Med Genet A       Date:  2010-10       Impact factor: 2.802

3.  Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations.

Authors:  Beatrice Primerano; Flora Tassone; Randi J Hagerman; Paul Hagerman; Francesco Amaldi; Claudia Bagni
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

4.  Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders.

Authors:  Silvia De Rubeis; Claudia Bagni
Journal:  J Neurodev Disord       Date:  2011-08-13       Impact factor: 4.025

Review 5.  The FMRP regulon: from targets to disease convergence.

Authors:  Esperanza Fernández; Nicholas Rajan; Claudia Bagni
Journal:  Front Neurosci       Date:  2013-10-24       Impact factor: 4.677

6.  EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders.

Authors:  Valérie Biancalana; Dieter Glaeser; Shirley McQuaid; Peter Steinbach
Journal:  Eur J Hum Genet       Date:  2014-09-17       Impact factor: 4.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.